9 Best Gene-Editing Stocks to Buy According to Hedge Funds

7. Krystal Biotech, Inc. (NASDAQ:KRYS)

Number of Hedge Fund Holders: 24

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, Inc. (NASDAQ:KRYS) stock and set a price target of $218.

In a different update, Krystal released its Q3 2025 results on November 3, in which the quarter’s EPS came in at $2.66 per diluted share against the anticipated $1.09. Revenue touched $97.8 million from its VYJUVEK product, bringing total revenue since the US launch to over $623 million. The quarter’s net income was $79.4 million. According to management, this growth was driven by manufacturing efficiencies and a one-time non-cash tax benefit. Also, gross margin improved to 96% during the quarter, up from 93% in the prior quarter due to US product manufacturing optimizations, as noted by management. As a result, the company ended the quarter with over $864 million in cash and investments.

In terms of operations, management emphasized that expansion into Germany, France, and Japan is underway. There are also partnerships in the Middle East, Turkey, and Central and Eastern Europe. The company also confirmed its ongoing focus on increasing patient access for the treatment of Dystrophic Epidermolysis Bullosa (DEB) and expanding its global market presence.

Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company. It develops and commercializes redosable gene therapies for rare and serious genetic diseases. Its first approved product, VYJUVEK, is the only FDA-approved redosable gene therapy for DEB, a severe skin disorder.